Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Sexual Behavior in Head and Neck Cancer Patients

Conditions: Oropharyngeal Cancer
Squamous Cell Carcinoma
Head and Neck Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2008-04-21

Last Posted Date: 2020-12-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1500

Registration Number: NCT00662662

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients

Phase 1

Completed

Conditions: Multiple Myeloma
Stem Cell Transplantation

Interventions: Drug: Arsenic Trioxide
Drug: Melphalan
Drug: Ascorbic Acid

First Posted Date: 2008-04-18

Last Posted Date: 2013-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00661544

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients

Completed

Conditions: Breast Cancer

Interventions: Procedure: CBCT Scan
Procedure: OBI KV Imaging

First Posted Date: 2008-04-14

Last Posted Date: 2015-10-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00658281

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Efficacy of the Third Eye Retroscope Auxiliary Imaging System

Not Applicable

Completed

Conditions: Colorectal Cancer

Interventions: Device: Third Eye Retroscope Auxiliary Imaging System

First Posted Date: 2008-04-14

Last Posted Date: 2013-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 288

Registration Number: NCT00657371

Locations: 🇺🇸
El Camino Hospital, Mountain View, California, United States
🇺🇸
Washington University, St. Louis, Missouri, United States
🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States

and more 4 locations

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Phase 2

Completed

Conditions: Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)

Interventions: Drug: Idarubicin
Drug: Cytarabine
Drug: Vorinostat

First Posted Date: 2008-04-11

Last Posted Date: 2015-03-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 106

Registration Number: NCT00656617

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status

Phase 2

Terminated

Conditions: Bronchiolitis

Interventions: Drug: Fluticasone Propionate

First Posted Date: 2008-04-11

Last Posted Date: 2012-04-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00656916

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

Phase 3

Completed

Conditions: Acute Myelogenous Leukemia
Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Procrit

First Posted Date: 2008-04-11

Last Posted Date: 2018-05-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT00656448

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

Phase 2

Completed

Conditions: Classic Hodgkin Lymphoma
Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
Lugano Classification Stage III Hodgkin Lymphoma AJCC v8

Interventions: Drug: Bleomycin
Drug: Dacarbazine
Drug: Doxorubicin Hydrochloride
Biological: Rituximab
Drug: Vinblastine

First Posted Date: 2008-04-09

Last Posted Date: 2020-02-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 58

Registration Number: NCT00654732

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Dasatinib in Resectable Malignant Pleural Mesothelioma

Phase 1

Completed

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: Dasatinib

First Posted Date: 2008-04-03

Last Posted Date: 2022-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 56

Registration Number: NCT00652574

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Phase 2

Completed

Conditions: Multiple Myeloma
Primary Amyloidosis

Interventions: Drug: Melphalan
Procedure: Stem Cell Infusion
Behavioral: Questionnaires
Drug: Granulocyte-colony stimulating factor (G-CSF)
Procedure: Apheresis

First Posted Date: 2008-04-03

Last Posted Date: 2020-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00651937

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy